Hidden within Teknova's latest earnings transcript (Q1 2024 Earnings Call) is a detail that could redefine the company's future: a small bottle of buffer named Build-Tek. This custom buffer configurator empowers researchers to order bespoke buffers in one-liter bottles with incredibly rapid turnaround times. No more minimum order quantities or weeks-long waits – just a few clicks and a couple of days later, the buffer is ready for scientific breakthroughs.

Targeting Untapped Potential: The Early-Stage Research Market

Build-Tek addresses a previously neglected market – the crucial early-stage research phase. Here, scientists often spend countless hours preparing buffers in small batches, a meticulous process that's essential but time-consuming. Teknova disrupts this paradigm by offering pre-made building blocks, allowing researchers to focus on higher-value tasks like designing experiments and analyzing data.

""Ultimately, this allows process development scientists to focus on advancing science instead of spending their time mixing buffers." - Stephen Gunstream, President and CEO of Teknova (Q1 2024 Earnings Call)"

Unlocking Efficiency and Growth

The potential impact of this shift is significant. Imagine the countless research labs globally, each with scientists meticulously preparing buffers. Build-Tek liberates them from this task, potentially accelerating the development of new therapies, diagnostics, and scientific discoveries.

Financial Performance and Outlook

Teknova reported a strong start to 2024 with revenue of $9.3 million, a 2% increase year-over-year. The company reiterated its 2024 total revenue guidance of $35 million to $38 million.

A Catalyst for Scientific Advancement

Build-Tek is more than just a product; it's a potential catalyst for scientific progress. By increasing research efficiency, it could contribute to faster development of groundbreaking solutions in life sciences.

"Fun Fact"

Teknova's headquarters are in Hollister, California, known as the "Earthquake Capital of the World." A fitting location for a company set to disrupt the life sciences industry.